Bioequivalence and pharmacokinetic research
The sponsor’s clinical programme is centred on bioequivalence studies in healthy volunteers, with a strong focus on comparing oral formulations and establishing pharmacokinetic similarity for marketed and generic medicines.
- Healthy volunteer studies
- Fed and fasting conditions
- Oral solid and oral suspension formulations
These studies support development work for antibacterial, antidiabetic, and other systemic therapies.
Antibacterial therapy
A major therapeutic area of interest is anti-infective treatment, particularly medicines used against bacterial infections and serious gram-negative pathogens.
- Amoxicillin and clavulanic acid
- Colistimethate sodium
- Serious bacterial infections
The sponsor’s research activity reflects continued attention to established antibiotic combinations and agents for limited-treatment-option settings.
Metabolic and endocrine medicines
The sponsor also funds clinical research in type 2 diabetes mellitus, with attention to SGLT2 inhibitor therapies used in routine metabolic care.
- Dapagliflozin
- Empagliflozin
- Insufficiently controlled type 2 diabetes
This area links the company’s formulation research with medicines used for long-term glycaemic control.
Cardiorenal disease
Another area of interest includes therapies relevant to symptomatic chronic heart failure and chronic kidney disease, both of which are important targets for modern cardiorenal treatment strategies.
- Heart failure
- Chronic kidney disease
- Cardiorenal medicine
Research activity in this domain aligns with medicines that are used across overlapping cardiovascular and renal indications.
